A Study to Evaluate the SYH2053 Injection in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)

NCT07465263 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

135

Enrollment

INDUSTRY

Sponsor class

Conditions

Heterozygous Familial Hypercholesterolemia (HeFH)

Interventions

DRUG: SYH2053 Injection
DRUG: Placebo Injection

Sponsor

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.